<b>Objectives:</b> To evaluate the utilization and outcomes of neoadjuvant chemotherapy (NACT) among patients with advanced-stage low- grade serous (LGSOC), clear cell (OCCC) and mucinous carcinoma (MOC) of the ovary. <b>Methods:</b> The National Cancer Database was accessed. Patients diagnosed between 2004 and 2015 with advanced-stage LGSOC, OCCC, MOC, and bulky intra-abdominal disease (TIIIC) who underwent debulking surgery received chemotherapy and had at least one month of follow-up were identified. We compared patients who underwent NACT versus PDS and defined their assigned cohort based on the timing of their chemotherapy and surgery administration. For analysis, we stratified by histology and evaluated overall survival with the log-rank test. In addition, Cox models were constructed to control for a priori selected confounders. <b>Results:</b> A total of 1893 patients were identified; 216 (11.4%) received NACT. Patients who received NACT were older (median 60 vs 56 years, p<0.001) and more likely to have government insurance (48.1% vs 34.5%, p<0.001). Rate of NACT was 13% for OCCC, 11.5% for LGSOC and 8.6% for MOC (p>0.05). Data on the residual disease status following debulking surgery was available for 625 patients; those who received NACT were more likely to have the macroscopic residual disease compared to patients who had PDS (68.8% vs 48.5%, p<0.001). For patients with LGSOC, NACT (<i>n</i>=69) was associated with worse OS compared to PDS (<i>n</i>=536) (p=0.018; median OS 54.97 vs 88.18 months). For patients with MOC, NACT (<i>n</i>=41) was associated with better OS compared to PDS (<i>n</i>=434) (p=0.038; median OS 18.86 vs 12.12 months). For patients with OCCC there was no difference between NACT (<i>n</i>=106) and PDS (<i>n</i>=707) (p=0.94; median OS 22.87 vs 23.06 months). After controlling for patient age, race, insurance, presence of comorbid conditions, disease stage, and debulking surgery complexity, NACT was associated with worse OS for LGSOC (HR: 1.49, 95% CI: 1.02-2.17), better OS for MOC (HR: 0.65, 95% CI: 0.45-0.94) and comparable OS for OCCC (HR: 0.95, 95% CI: 0.74-1.21). <b>Conclusions:</b> Neoadjuvant chemotherapy is rarely utilized among patients with chemo-resistant ovarian histotypes and may be associated with poor outcomes for patients with LGSOC. For patients with MOC and OCCC, outcomes appear to be comparable to PDS.